NCT06368141View on ClinicalTrials.gov

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

April 30, 2026

Conditions
Colon Cancer
Interventions
DRUG

Serplulimab

Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

DRUG

Capecitabine

Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

DRUG

Oxaliplatin

Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER